FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer


Today, as part of Project Orbis, the U.S. Food and Drug Administration approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can't be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one or more prior treatments.

The FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA, Singapore) and Swissmedic (SMC, Switzerland) on this review. This is the first Project Orbis partnership between the FDA, HSA and Swissmedic. While the FDA approved Tukysa today, the application is still under review at the other agencies. Collaboration among international regulators may allow patients with cancer to receive earlier access to products in other countries where there may be significant delays in regulatory submissions, regardless of whether the product has received FDA approval. Early availability of new therapies and adoption as standard of care around the world may have an impact on the increasingly international conduct of cancer clinical trials, potentially accelerating the development of anticancer products. With a framework for concurrent submission and review of oncology drugs, Project Orbis facilitates a collaborative review to identify any regulatory divergence across review teams.

"The FDA's Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA's international collaborators. We are pleased to work with our Singapore and Switzerland colleagues for the first time, and to continue working alongside our Australian and Canadian colleagues as we facilitate new treatment options for patients - like today's first new molecular entity under Project Orbis," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research. "This approval represents an additional targeted treatment option for patients with HER2-positive breast cancer. The clinical trial supporting this approval enrolled and specifically studied patients with active brain metastases in addition to the overall population enrolled, which also demonstrated benefit in this subgroup." HER2-positive breast cancer, which makes up approximately one-fifth of breast cancers, has too much of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. More than 25% of women with metastatic HER2-positive breast cancer will develop brain metastases.

"We recognize that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease," said Pazdur. "In this critical time, we remain steadfast in our commitment to patients with cancer and doing everything we can to expedite oncology product development. Tukysa was approved four months prior to the FDA goal date, providing an example of this commitment and showing how our regular work in reviewing treatments for patients with cancer is moving forward without delay."

Tukysa is a kinase inhibitor meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing. Tukysa is approved for treatment after patients have taken one or more anti-HER2-based regimens in the metastatic setting. The FDA approved Tukysa based on the results of a clinical trial enrolling 612 patients who had HER2-positive advanced unresectable or metastatic breast cancer and had prior treatment with trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1). Patients with previously treated and stable brain metastases, as well as those with previously treated and growing or untreated brain metastases, were eligible for the clinical trial, and 48% of enrolled patients had brain metastases at the start of the trial.

The primary endpoint was progression-free survival (PFS), or the amount of time when there was no growth of the tumor. The median PFS in patients who received Tukysa, trastuzumab, and capecitabine was 7.8 months compared to 5.6 months in those patients who received placebo, trastuzumab, and capecitabine. Overall survival and PFS in patients with brain metastases at baseline were key secondary endpoints. The median overall survival in patients who received Tukysa, trastuzumab, and capecitabine was 21.9 months compared to 17.4 months in patients who received placebo, trastuzumab, and capecitabine. The median PFS in patients with brain metastases at baseline who received Tukysa, trastuzumab and capecitabine was 7.6 months compared to 5.4 months in patients who received placebo, trastuzumab and capecitabine. Common side effects for patients taking Tukysa were diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips), decreased appetite, abdominal pain, headache, anemia and rash.

Tukysa can cause serious side effects including severe diarrhea associated with dehydration, acute kidney injury and death. Health care professionals should advise patients to notify their health care provider and start antidiarrheals as clinically indicated if diarrhea occurs. If patients are experiencing severe diarrhea, Tukysa should be interrupted or the dosage reduced. Tukysa can also cause severe hepatotoxicity. Health care professionals should monitor liver tests in patients taking Tukysa every three weeks while the patient is on treatment or as clinically indicated.

Women who are pregnant or breastfeeding should not take Tukysa because it may cause harm to a developing fetus or newborn baby. The FDA advises health care professionals to tell females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Tukysa and for at least one week after the last dose. The FDA also advises patients refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy and contraception information. In addition to the international collaboration with TGA, Health Canada, HSA Singapore and SMC Switzerland, this review used the Real-Time Oncology Review (RTOR) pilot program, which can streamline the submission of data prior to the completion and submission of the entire clinical application. RTOR, as well as the Assessment Aid, facilitated discussions among the regulatory agencies and regulatory review.

The FDA granted this application Priority Review and Breakthrough Therapy designation, which expedites the development and review of drugs that are intended to treat a serious condition, when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. Tukysa was also granted Fast Track designation, which expedites the review of drugs to treat serious conditions and fill an unmet medical need. Tukysa received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The FDA granted approval of Tukysa to Seattle Genetics, Inc.

More Resources

Unable to open RSS Feed $XMLfilename with error HTTP ERROR: 404, exiting

More Breast Cancer Information:

Related Articles

Breast Cancer The Cure
You have my permission to publish this article electronically or in print, free of charge, as long as the bylines are included. A courtesy copy of your publication would be appreciated.
Mammograms Are No Joke - They Can Save Lives!
There are so many jokes about mammograms! Have you heard the one about the fridge door ?or the bookends ?or the garage floor? Thanks to all the jokes, "Mammogram" has become a household word, and it's not that I don't have a sense of humor, but as a mammography technologist, I've heard the jokes many times. I think the jokes are embarrassing for women and demeaning with regard to their physical bodies.
Emotional Responses to Breast Cancer - Understanding the One You Love
Being diagnosed with breast cancer is a life-changing event. A torrent of feelings wash over the survivor.
Your Risk of Cancer Can Increase With Weight Gain!
We hear it all the time?lose weight for your health. Few people however, realize the extent to which this is critical to their physical well-being and ultimately their life expectancy.
The Insidiousness of Breast Cancer and Its Current Treatment
In our modern world, the benefits that today's manufacturing and agricultural activities have brought us is more than painfully offset by the damage to our personal health and wellness. During the course of our daily lives, we are continually exposed to common household products such as detergents, insulation, fabric treatments, flame retardants, cosmetics, paints, upholstery preservatives, and coatings for electronic equipment.
Breast Cancer Screening
Breast cancer is the second most common cancer women face second only to lung cancer, however it is the most feared cancer or disease for most women. It occurs in about 12% of women who will live to the age of 90.
Are Obese Women Getting Short-Changed By Chemotherapy Treatments?
How much chemotherapy does an obese woman need? Typically an obese woman with breast cancer would receive reduced doses of chemotherapy as they battle breast cancer.Back in June of 2005, a study published in the Archives of Internal Medicine concluded that obese women should receive chemotherapy based on their actual weight, and not in reduced as amounts as it the standard practice.
Early Breast Cancer Detection
Most women are familiar with mammography as our "gold standard" for breast cancer screening. However, there are additional tools available that women can add to their arsenal.
New Hope to Prevent Breast Cancer: What Every Woman Needs to Know
In March, 2005, a major nutritional breakthrough in the fight against breast cancer was announced by U.S.
Breast Cancer - 101
The cancer is a term for diseases in which abnormal cells divide uncontrollably invading near by tissue and spreading to other parts of the body via blood stream or lymphatic system.Similarly, in breast cancer, a single cell begins to divide and grow abnormally.
Breast Cancer
In December of 2001, breast cancer was the furthest thing from my mind. I was busy.
My First Thermographic Experience
I had been a bit nervous all day wondering what my thermogram procedure would entail. Would I need to undress completely? Would I be given one of those paper gowns that opens in the front and barely covers me? Would there be any heat coming out of the camera? I had been avoiding a mammogram after reading the latest information about the risks associated with X-ray; knowing that I was potentially putting myself at greater risk by not taking charge of my health.
Antiperspirants And Breast Cancer
Most underarm antiperspirants contain as the active ingredient, Aluminium Chlorohydrate, as you will probably remember there has been controversy about Aluminium, since the 1950's when it was a popular metal used for making cooking pots, Saucepans and Fry Pans and that it could be one of the contributing factors to Alzheimer's, now we have another problem that could also be related to Aluminium, Breast Cancer.Research shows that one of the leading causes of Breast Cancer could be the use of antiperspirants.
Can You Reduce Your Risk of Breast Cancer?
We hear it all the time?lose weight for your health. Few people however, realize the extent to which this is critical to their physical well-being and ultimately their life expectancy.
Finding Your Spiritual Strength in the Midst of Your Emotional Turmoil
There were so many emotions that I experienced in 2003 when the doctor confirmed I had Breast Cancer; I was overwhelmed. That was a point in my life that seemed to play out in slow motion.
Recommendations For Early Breast Cancer Screening
Women need to empower themselves about the benefits and risks of mammography and examine the additional screening tools available today. One current philosophy suggests breast health screening should begin at age 25.
Breast Cancer for Beginners
IntroductionBecause of the social changes, which has brought increased number of workingwoman and hence delayed childbearing, there has been a steep rise in the number of breast cancer patients in the last few decades. But as the incidence of the patients has risen so has raised the modality of treatments and the success rates.
Digital Infrared Thermal Imaging In Medical Therapy
Digital technology now makes Digital Infrared Thermal Imaging available to all. There now is a completely safe test that can aid in diagnosis, treatment and monitoring with absolutely no risk or radiation exposure.
New Advances In Early Breast Cancer Detection
In November 2003, the American Cancer Society stated that breast cancer is the leading cause of death in women between the ages of 40 and 44. In the United States, there are approximately 200,000 new cases of breast cancer and more than 40,000 deaths; making the U.
Screening For Breast Cancer With No Compression And No Radiation
Who would have thought that a technology for detecting breast cancer used today actually had its' roots dating back to 480 B.C.